Literature DB >> 25022955

IL-32γ overexpression accelerates streptozotocin (STZ)-induced type 1 diabetes.

Hyunjhung Jhun1, Jida Choi1, Jaewoo Hong1, Siyoung Lee1, Areum Kwak1, Eunsom Kim1, Seunghyun Jo1, Soyoon Ryoo1, Yoojung Lim1, Do-Young Yoon2, Jin Tae Hong3, Tae Sung Kim4, Youngmin Lee5, Keeho Song6, Soohyun Kim7.   

Abstract

Interleukin-32 (IL-32) is a cytokine produced by T lymphocytes, natural killer (NK) cells, monocytes and epithelial cells. There are five splicing variants (α, β, γ, δ, and ε) and IL-32γ is the most active isoform. We generated human IL-32γ transgenic (IL-32γ TG) mice, displaying a high level of IL-32γ expression in the pancreas. We investigated the effect of IL-32γ on streptozotocin (STZ)-induced type 1 diabetes model using IL-32γ TG mice. After a suboptimal diabetogenic dose of STZ administration, IL-32γ TG mice showed significantly increased blood glucose level comparing with that of wild type (WT) mice at day 5. Inflammatory cytokines levels such as, IL-6, TNFα, IFNγ and IL-1β, in pancreas and liver lysates were accessed by a specific cytokine ELISA. The proinflammatory cytokines were significantly enhanced in the pancreas of IL-32γ TG mice comparing to that of WT mice whereas those cytokines levels in liver of IL-32γ TG and WT mice were not changed by STZ. These data indicate that the overexpression of IL-32γ contributes to initial islet β-cells injury and inflammation in pancreas and aggravates STZ-induced type 1 diabetes.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Glucose tolerance test; IL-32γ transgenic mice; Inflammatory cytokine; Pancreas; Streptozotocin (STZ)-induced type I diabetes

Mesh:

Substances:

Year:  2014        PMID: 25022955     DOI: 10.1016/j.cyto.2014.05.002

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  4 in total

Review 1.  Altered Expression of Transporters, its Potential Mechanisms and Influences in the Liver of Rodent Models Associated with Diabetes Mellitus and Obesity.

Authors:  Leilei Ma; Lei He; Le Wang; Li Li; Xuena Lin; Guoyu Pan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-06       Impact factor: 2.441

2.  Interleukin-32α Inhibits Endothelial Inflammation, Vascular Smooth Muscle Cell Activation, and Atherosclerosis by Upregulating Timp3 and Reck through suppressing microRNA-205 Biogenesis.

Authors:  Dong Ju Son; Yu Yeon Jung; Young Sik Seo; Heonyong Park; Dong Hun Lee; Sanghyeon Kim; Yoon-Seok Roh; Sang Bae Han; Do Young Yoon; Jin Tae Hong
Journal:  Theranostics       Date:  2017-06-01       Impact factor: 11.556

3.  IL-32-induced Inflammatory Cytokines Are Selectively Suppressed by α1-antitrypsin in Mouse Bone Marrow Cells.

Authors:  Siyoung Lee; Dong-Ki Choi; Areum Kwak; Sinae Kim; Tam Thanh Nguyen; Gaae Gil; Eunhye Kim; Kwang Ha Yoo; In Ae Kim; Youngmin Lee; Hyunjhung Jhun; Edward D Chan; Xiyuan Bai; Hyunwoo Kim; Yong-Sung Kim; Soohyun Kim
Journal:  Immune Netw       Date:  2017-04-20       Impact factor: 6.303

4.  Comparison of the Seven Interleukin-32 Isoforms' Biological Activities: IL-32θ Possesses the Most Dominant Biological Activity.

Authors:  Saerok Shim; Siyoung Lee; Yasmin Hisham; Sinae Kim; Tam T Nguyen; Afeisha S Taitt; Jihyeong Hwang; Hyunjhung Jhun; Ho-Young Park; Youngmin Lee; Su Cheong Yeom; Sang-Yeob Kim; Yong-Gil Kim; Soohyun Kim
Journal:  Front Immunol       Date:  2022-02-25       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.